🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Regorafenib

    United Therapeutics Europe Ltd

    Gastro-Oesophageal Cancer

    phase 3 small molecule active

    1 trial

  2. Regorafenib (BAY73-4506)

    Bayer HealthCare AG

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  3. Relacorilant

    CORCEPT THERAPEUTICS INC

    Hypercortisolism

    phase 3 small molecule completed

    1 trial

  4. Relacorilant, 100 mg and 25 mg

    CORCEPT THERAPEUTICS INC

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule terminated

    1 trial

  5. Remdesivir

    The First People's Hospital of Lianyungang

    Covid19

    phase 3 small molecule active

    1 trial

  6. Remimazolam Besylate

    The First People's Hospital of Lianyungang

    Critical Illness; Mechanical Ventilation; Shock

    phase 3 small molecule active

    1 trial

  7. Remodulin (treprostinil sodium) Injection

    United Therapeutics Europe Ltd

    Peripheral Vascular Disease

    phase 3 small molecule terminated

    1 trial

  8. Remodulin® (treprostinil sodium) Injection

    United Therapeutics Europe Ltd

    Critical Limb Ischemia

    phase 3 small molecule terminated

    1 trial

  9. Remternetug, Placebo to match LY

    Eli Lilly Co.

    Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  10. Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS)

    Pari Pharma GmbH

    Remyelination in Multiple Sclerosis

    phase 3 other active

    1 trial

  11. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye

    phase 3 small molecule completed

    4 trials

  12. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Allergic Conjunctivitis

    phase 3 small molecule completed

    4 trials

  13. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Disease

    phase 3 small molecule completed

    4 trials

  14. Reproxalap Ophthalmic Solution (0.25%) QID

    Aldeyra Therapeutics

    Dry Eye

    phase 3 small molecule completed

    1 trial

  15. Retifanlimab (INCMGA00012), CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Bendatax 6 mg/ ml, Placebo liquid (not containing the active substance, otherwise identical to INCMGA0012)

    Incyte

    Squamous Carcinoma of the Anal Canal

    phase 3 small molecule active

    1 trial

  16. Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 25 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 10 mg powder and solvent for solution for injection for paediatric use, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempi

    The George Institute

    juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  17. Revatio 0.8 mg/ml solution for injection

    Pari Pharma GmbH

    Hypoxic ischemic encephalopathy

    phase 3 small molecule active

    1 trial

  18. Revefenacin

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease, COPD

    phase 3 small molecule completed

    2 trials

  19. Revlimid 10 mg hard capsules, DIPHENHYDRAMINE , Revlimid 20 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 5 mg hard capsules, Revlimid 10 mg hard capsules, Isatuximab, Revlimid 25 mg hard capsules, Zelvina 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Zelvina 10 mg hard capsules, PARACETAMOL , Zelvina 20 mg hard capsules, MONTELUKAST , METHYLPREDNISOLONE , Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Zelvina 15 mg hard capsules, Isa

    Sanofi-aventis Healthcare Pty Ltd

    Plasma cell myeloma

    phase 3 small molecule active

    1 trial

  20. Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s

    Incyte

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial

  21. Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 25 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 5 mg hard capsules, Isatuximab, Zelvina 10 mg hard capsules, Revlimid 10 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 15 mg hard capsules, Revlimid 10 mg hard capsules, Zelvina 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Zelvina 5 mg hard capsules, Revlimid 25 mg hard capsules,

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 3 small molecule active

    1 trial

  22. Revumenib

    United Therapeutics Europe Ltd

    Acute Myeloid Leukemia, Adult

    phase 3 small molecule active

    1 trial

  23. Revusiran (ALN-TTRSC)

    Alnylam Netherlands B.V.

    Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

    phase 3 small molecule completed

    1 trial

  24. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Genotype 1 Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources